PVI
BCRX icon

Pura Vida Investments’s BioCryst Pharmaceuticals BCRX Stock Holding History

Pura Vida Investments’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-116,800
Closed -$401K – 184
2020
Q3 		$401K Buy
+116,800
New +$501K 0.02% 143

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Pura Vida Investments's BCRX Position: Q1 2023 in Review

Pura Vida Investments sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2023, closing a stake of 106,629 shares — an estimated $1.22M sold.

Pura Vida Investments first reported a position in BCRX in Q2 2017 and held it in 10 quarters. The position peaked at $7.52M in Q4 2019. 241 funds tracked by Wall St. Rank hold BCRX as of Q1 2023.

  • Pura Vida Investments reported no remaining BioCryst Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Pura Vida Investments sold 106,629 BioCryst Pharmaceuticals shares in Q1 2023, an estimated $1.22M.
  • Pura Vida Investments first reported a position in BioCryst Pharmaceuticals in Q2 2017 and held it in 10 quarters.
  • Pura Vida Investments's BioCryst Pharmaceuticals position peaked at $7.52M in Q4 2019.
  • 241 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2023.

Based on Pura Vida Investments's 13F filing for Q1 2023, filed 15 May 2023.